Opinion|Videos|November 1, 2024
Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
Panelists discuss how referral types for multiple myeloma patients vary widely, including newly diagnosed cases, relapsed/refractory disease, and specific therapy considerations like bispecifics, with processes differing between in-state and out-of-state referrals due to logistical and insurance factors.
Advertisement
Video content above is prompted by the following:
- What types of referrals do you usually do?
- Is the process similar/different for in-state vs out-state?
- How do social factors play into the referral process?
- How do the AEs differ based on the class of bispecific? Which AEs are you seeing in practice?
- How are they managed?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
2
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
3
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
4
Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia
5